163 related articles for article (PubMed ID: 16126738)
21. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results.
Zambetti M; Valagussa P; Bonadonna G
Ann Oncol; 1996 Jul; 7(5):481-5. PubMed ID: 8839902
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
Land SR; Kopec JA; Yothers G; Anderson S; Day R; Tang G; Ganz PA; Fisher B; Wolmark N
Breast Cancer Res Treat; 2004 Jul; 86(2):153-64. PubMed ID: 15319567
[TBL] [Abstract][Full Text] [Related]
23. Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment.
Niikura N; Kimura M; Iwamoto T; Hayashi N; Shintoku J; Saito Y; Suzuki Y; Tokuda Y
Breast Cancer; 2013 Jan; 20(1):67-74. PubMed ID: 22109640
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
[TBL] [Abstract][Full Text] [Related]
25. Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer.
Blinman P; Martin A; Jefford M; Goldstein D; Boadle D; Morris M; Tebbutt N; Aiken C; Harkin A; Segelov E; Haydon A; Iveson T; Stockler MR
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 34159294
[TBL] [Abstract][Full Text] [Related]
26. Multi-agent chemotherapy for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2002; (1):CD000487. PubMed ID: 11869577
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
28. Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'.
Demicheli R; Miceli R; Brambilla C; Ferrari L; Moliterni A; Zambetti M; Valagussa P; Bonadonna G
Breast Cancer Res Treat; 1999 Feb; 53(3):209-15. PubMed ID: 10369067
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival.
Gelber RD; Cole BF; Goldhirsch A; Bonadonna G; Howell A; McArdle CS; Mouridsen HT; Rubens RD; Welvaart K
Cancer J Sci Am; 1995; 1(2):114-21. PubMed ID: 9166464
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant systemic therapy for women with node-negative breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S43-51. PubMed ID: 9484278
[TBL] [Abstract][Full Text] [Related]
31. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Ploner F; Jakesz R; Hausmaninger H; Kolb R; Stierer M; Fridrik M; Steindorfer P; Gnant M; Haider K; Mlineritsch B; Tschurtschenthaler G; Steger G; Seifert M; Kubista E; Samonigg H;
Onkologie; 2003 Apr; 26(2):115-9. PubMed ID: 12771518
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
33. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New.
Cho E; Schwemm AK; Rubinstein LM; Stevenson PA; Gooley TA; Ellis GK; Specht JM; Livingston RB; Linden HM; Gadi VK
Clin Breast Cancer; 2015 Oct; 15(5):e277-85. PubMed ID: 26025883
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study.
Montagna E; Pagan E; Bagnardi V; Colleoni M; Cancello G; Munzone E; Dellapasqua S; Bianco N; Campennì G; Iorfida M; Mazza M; De Maio A; Veronesi P; Sangalli C; Scateni B; Pettini G; Pravettoni G; Mazzocco K; Galimberti V
Breast Cancer Res Treat; 2020 Dec; 184(3):783-795. PubMed ID: 32929568
[TBL] [Abstract][Full Text] [Related]
36. Patients' preferences for chemotherapy in non-small-cell lung cancer: a systematic review.
Blinman P; Alam M; Duric V; McLachlan SA; Stockler MR
Lung Cancer; 2010 Aug; 69(2):141-7. PubMed ID: 20570009
[TBL] [Abstract][Full Text] [Related]
37. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
[TBL] [Abstract][Full Text] [Related]
38. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy.
Joly F; Espié M; Marty M; Héron JF; Henry-Amar M
Br J Cancer; 2000 Sep; 83(5):577-82. PubMed ID: 10944595
[TBL] [Abstract][Full Text] [Related]
39. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
Hartman AR; Fleming GF; Dillon JJ
Clin Breast Cancer; 2001 Jul; 2(2):138-43; discussion 144. PubMed ID: 11899785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
